Immune cell dynamics drive progression from acute to chronic pancreatitis

Pancreatitis is clinically classified into acute pancreatitis (AP) and chronic pancreatitis (CP). Most patients with AP recover without residual pancreatic dysfunction; a subset develops recurrent AP, and only selected high-risk individuals—particularly those with ongoing etiological exposure, genetic susceptibility, or severe necrotizing disease—progress to CP. The mechanisms underlying this progression remain poorly understood.

In AP, rapid infiltration of neutrophils and M1-like macrophages drives tissue injury through cytokine release, neutrophil extracellular traps, and inflammasome activation, while  T helper 17 (Th17) cells amplify inflammation. Resolution depends on phenotypic switching: M1-like macrophages shift to reparative M2-like states, regulatory T cells (Tregs) expand, and dendritic cells shift from pro-inflammatory to regulatory functions. Persistent injury disrupts this balance. In CP, macrophages become trapped in an incomplete M2-like polarization, retaining pro-inflammatory features while acquiring pro-fibrotic functions; pathogenic Th17 cells persist and directly activate pancreatic stellate cells (PSCs) via IL-17A and IL-22; Tregs undergo functional failure; and neutrophil activity becomes scattered and residual.

Metabolic reprogramming underpins these transitions. In AP, ketogenesis restrains macrophage hyperactivation and NLRP3 signaling, whereas impaired fatty acid oxidation and mitochondrial dysfunction in CP lock macrophages into glycolytic, pro-fibrotic phenotypes. Th17 cells adopt glycolysis to sustain IL-17 production, while Treg suppression depends on oxidative phosphorylation that is compromised in chronic disease. Iron overload and dysregulated neddylation further amplify oxidative stress and fibrotic signaling. These changes converge on PSC activation, establishing self-sustaining fibrotic loops.

The review, published in Volume 9, Issue 3 of the Journal of Pancreatology in September 2026, delineates spatiotemporal dynamics of innate and adaptive immune cells across disease phases and identifies therapeutic opportunities targeting macrophage polarization, Th17/Treg balance, PSC–immune crosstalk, and metabolic checkpoints. It was based on a PubMed search supplemented by Embase and Web of Science, restricted to English articles published from January 2016 to July 2026, with the exception of seminal studies identified through cross-referencing.

Reference
Title of original paper: From acute pancreatitis to recurrent acute and chronic pancreatitis: Dynamic
evolution of immune responses
Journal: Journal of Pancreatology
DOI: http://dx.doi.org/10.1097/JP9.0000000000000278

About Journal of Pancreatology
Journal of Pancreatology (The JP) is an international, peer-reviewed, open-access medical journal focusing on pancreatic diseases. The JP is the official journal of the Chinese Association of Pancreatology (CAP), sponsored by the Chinese Medical Association (CMA), and published quarterly in English both in print and online issues by Chinese Medical Journals Publishing House Co., Ltd. The JP is distributed globally by Lippincott Williams & Wilkins.

Why Publish with the JP

1. Focus on pancreatic disease-related epidemiology, clinical, translational research, and frontiers.
2. The journal has been indexed by ESCI, DOAJ, Scopus, Embase, CSTPC, etc.
3. Rapid decision-making: First decision within 14 days, online publication within 2 months.
4. Fully open access and free overseas media promotion (including X, LinkedIn, EurekAlert, etc).
   Website: https://www.ovid.com/jnls/jpancreatology

Author Introduction
Li Wen, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China. E-mail: wenli7007@gmail.com
Dong Shang, Clinical Key Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China. E-mail: shangdong@dmu.edu.cn

Funding Information
This work is supported by the National Natural Science Foundation of China (82570768 and 12411530128), the CAMS Innovation Fund for Medical Sciences (2023-I2M-3-001), and Peking Union Medical College Hospital Talent Cultivation Program (Category B, No. UGG06642).